Progress report on the first sub-Saharan trial of newer versus older ... - 7thSpace Interactive (press release)
Progress report on the first sub-Saharan trial of newer versus older .
Novartis profit falls on generic competition and charges - PMLiVE
AFPNovartis profit falls on generic competition and chargesPMLiVERevenues fell 2 per cent to $13.
Novartis Pressures Generics Makers Over Exforge ANDA - Law360 (subscription)
Novartis Pressures Generics Makers Over Exforge ANDALaw360 (subscription).
Novartis: A Sleeper Or A Headache? - Seeking Alpha
Novartis: A Sleeper Or A Headache?Seeking AlphaThis last quarter, Novartis missed the street estimates mainly because of looming patent expiration of some of their best-selling prescription drugs, most notably Diovan (valsartan).
ValueWalkTweedy Browne Recently portfolio MovesValueWalkThe company manufactures a wide variety of drugs including diclofenac, slozapine, carbamazepne and valsartan.